

INDEX

A

Agarose gel electrophoresis.....207–210
 AlamarBlue 119, 121
 Alternative splicing..... 31, 202, 207
 Angiogenesis assay.....107–114
 Animals 79, 81, 84, 109, 110, 114, 118,
 130, 134, 135, 160, 161
 Antibody..... 71, 73, 74, 134, 152, 154,
 155, 183, 190, 192
 Antibody array.....189–199
 Apoptosis.....21, 45
 Autophagy.....151–162

B

Bioanalyzer..... 14, 16, 17, 22, 25, 26, 33,
 35, 39, 41, 47, 48, 51–52, 57, 65, 66
 Biodegradable..... 1, 2, 126
 Biological fluids81
 Biomarkers 14, 22, 83, 202
 Biotinylated proteins190
 Bisulfite sequencing.....71
 Blood vessels.....107–109
 Boyden chamber.....108
 Breast cancer.....13–18, 67, 90, 94, 182
 Buffy coat13–19

C

CAM assay. *See* Chorioallantoic membrane (CAM) assay
 Cancer 1, 5, 13, 21–28, 31–43, 45–67,
 69–75, 77, 78, 89, 99–104, 107, 118–128, 139, 140,
 151–162, 165–179, 181, 189–199, 202
 Cancer stem cells (CSCs) 119, 130, 131, 134
 Cell cycle 149, 159
 Cell labeling185
 Cell proliferation 14, 21, 108, 183
 Chemoprevention.....21–28, 31–43,
 45–67, 77–87, 89–96, 99–104, 122, 129–137, 151–162,
 165–179, 189–199, 201–210
 Chemoresistance.....99, 131, 135–136, 139–149
 Chip. *See* Chromatin Immunoprecipitation (ChIP)
 Chorioallantoic membrane (CAM) assay..... 108–110,
 112–114

Chromatin69, 70
 Chromatin immunoprecipitation (ChIP)..... 25, 42, 51
 Circulating tumor DNA.....45–67
 Clonogenic assay141
 Comet assay.....99–104
 Conditioned medium 134, 137, 144, 147
 Confocal microscopy154–158, 162, 185, 186
 Coomassie staining.....170, 171
 CpG islands.....70
 CSCs. *See* Cancer stem cells (CSCs)

D

DNA damage 99, 100, 103
 Drug delivery systems.....1

E

Eggs..... 109, 112–114, 185
 Encapsulation.....2
 Enzyme-linked immunosorbent assay
 (ELISA) 166, 190, 197
 Epigenetic remodeling.....69–75
 Extracellular matrix (ECM)118

F

FACS.....132, 134, 141, 143,
 145–146, 149
 Fluorophore..... 166, 167, 169,
 177, 178, 184
 Fresh tissues.....21–28
 Fluorescence resonance energy transfer
 (FRET assay).....165–179

G

Gene expression.....13, 16, 21, 22, 28,
 40, 69, 70, 130

H

High-throughput analysis13

I

Immunoprecipitation..... 31, 72, 73

L

Liquid chromatography mass spectrometry (LC-MS)77–87
Liposomes2

M

Matrigel.....108, 109, 111–112, 132, 135, 182
Mesothelioma..... 22, 140, 141, 143, 144, 189
Messenger RNAs (mRNAs)..... 13, 14, 21, 22, 25, 32, 42, 125, 201, 202, 209
Metabolomics 77–87, 89–96
Methylated DNA immunoprecipitation (MeDIP).....69–75
Micelles2
Micro array analysis..... 18, 192
Microparticles.....2
MicroRNA profiling 13–18, 146
MicroRNAs (miRNAs)..... 13–18, 21–28
mRNAs
Messenger RNAs (mRNAs)

N

Nanoparticles..... 2, 119, 120, 122–125, 127, 128
Natural agents 189–199
Next-generation sequencing..... 31, 45, 46, 71
Noncoding RNAs..... 13, 21
Non-small-cell lung cancer cells (NSCLCs) 119, 120
Nuclear magnetic resonance (NMR)..... 89–96

P

Patient-derived xenograft (PDXs).....130
Phospho-protein..... 190, 197
Plasma-seq 46, 60, 67
Primary cultures..... 139, 140, 144, 147–149
Proteomics.....78

R

Retinoic acid (RA) 17, 70
RNA immunoprecipitation sequencing (RIP-Seq)31
RNA-sequencing (RNA-seq)..... 28, 31–43

S

Single strand breaks (SSB)100
Spheroids..... 118–128

T

Three dimensional (3D) cultures..... 99, 118–122, 126, 127, 181, 182, 185, 187
Thymoma22
Time-lapse imaging..... 181–188
Toxicity..... 1, 2

U

Ultra-performance liquid chromatography (UPLC) 80, 82

W

Western blotting.....120